STOCK TITAN
  1. Home
  2. Sec-filings
  3. MPLT
  4. [8-K] MapLight Therapeutics, Inc. Reports Material Event

MapLight Therapeutics (MPLT) board shifts as two directors exit, two nominated

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. reported that directors Robert Malenka, M.D., Ph.D. and Jim Trenkle, Ph.D. have decided not to stand for reelection at the company’s Annual Meeting of Stockholders scheduled for June 23, 2026. The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace them. The company stated that Dr. Malenka’s and Dr. Trenkle’s decisions were not due to any disagreement with MapLight on its operations, policies, or practices.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Notice date April 23, 2026 Date directors notified the Board they would not stand for reelection
Annual meeting date June 23, 2026 Scheduled date of Annual Meeting of Stockholders
Par value per share $0.0001 per share Voting Common Stock par value
Annual Meeting of Stockholders financial
"not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026"
Class I director nominees financial
"The Board has nominated Martin Babler and Troy Cox as Class I director nominees"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nasdaq Global Select Market financial
"MPLT | | Nasdaq Global Select Market"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
Understanding 8-K Material Events →
false 0001770069 0001770069 2026-04-23 2026-04-23
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 23, 2026

 

 

MapLight Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-42914   83-2163243
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

800 Chesapeake Drive
Redwood City, California 94063
(Address of principal executive offices)

Registrant’s telephone number, including area code: (617) 984-6300

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
symbol(s)

  

Name of each exchange
on which registered

Voting Common Stock, $0.0001 par value per share   MPLT   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the “Board”) of MapLight Therapeutics, Inc. (the “Company”) of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026. The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.

Dr. Malenka’s and Dr. Trenkle’s decisions not to stand for reelection were not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MapLight Therapeutics, Inc.
Dated: April 29, 2026     By:  

/s/ Christopher A. Kroeger

      Christopher A. Kroeger, M.D.
      Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What board changes did MapLight Therapeutics (MPLT) disclose in this 8-K?

MapLight Therapeutics disclosed that directors Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., chose not to stand for reelection. The Board nominated Martin Babler and Troy Cox as Class I director nominees to replace them at the upcoming Annual Meeting of Stockholders.

When is MapLight Therapeutics’ 2026 Annual Meeting of Stockholders scheduled?

The Annual Meeting of Stockholders for MapLight Therapeutics is scheduled for June 23, 2026. At this meeting, shareholders are expected to vote on Class I director nominees, including proposed replacements for directors who are not standing for reelection.

Why are MapLight Therapeutics directors Malenka and Trenkle leaving the board?

Directors Robert Malenka and Jim Trenkle informed the Board they will not stand for reelection at the June 23, 2026 Annual Meeting. The company stated their decisions were not due to any disagreement regarding operations, policies, or practices.

Who has MapLight Therapeutics nominated to replace the departing directors?

The Board of MapLight Therapeutics has nominated Martin Babler and Troy Cox as Class I director nominees. They are intended to replace directors Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., who decided not to stand for reelection at the 2026 Annual Meeting.

Did MapLight Therapeutics report any disagreements with the departing directors?

MapLight Therapeutics specifically stated that the decisions by Dr. Robert Malenka and Dr. Jim Trenkle not to stand for reelection were not due to any disagreement with the company on matters relating to its operations, policies, or practices, indicating an orderly transition.

On what stock exchange is MapLight Therapeutics (MPLT) listed?

MapLight Therapeutics’ Voting Common Stock, $0.0001 par value per share, trades on the Nasdaq Global Select Market under the symbol MPLT. This listing detail was confirmed in the company’s disclosure about its board and governance changes.

Filing Exhibits & Attachments

3 documents

Other Documents